For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Quotient Sciences, Vasa Therapeutics dose first human subjects with VS-041, a novel therapy for heart failure with preserved ejection fraction: Nottingham, UK Monday, September 16 ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...